Industry Insights
Sep 03, 2026 · 1 min read · 38,672 views
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
A
Aiden Brooks
Editorial · Sep 03, 2026
Bristol Myers Squibb spinout Beeline Medicines is getting extra love from its existing backers and some of its management team. Bain Capital, the Canada Pension Plan Investment
← Previous
Updated: Roivant reports Phase 2b lupus failure for an FcRn drug
Next →
Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal
